home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9407f.zip
/
M9471086.TXT
< prev
next >
Wrap
Text File
|
1994-08-09
|
3KB
|
46 lines
Document 1086
DOCN M9471086
TI Clinical trial and post-marketing safety profile of Filgrastim in
oncology patients (Neupogen) (Meeting abstract).
DT 9409
AU McLeish S; Decoster G; Rich W; Amgen Inc., Thousand Oaks, CA 91320-1789
SO Proc Annu Meet Am Soc Clin Oncol; 13:A543 1994. Unique Identifier :
AIDSLINE ICDB/94600539
AB Filgrastim (Neupogen) is widely used in oncology patients to decrease
the incidence of infection as manifested by febrile neutropenia. We have
reviewed the safety profile for Filgrastim from pre-marketing studies in
oncology patients. This included data from 638 patients who participated
in 14 clinical studies. These cancer patients received standard or high
dose chemotherapy (CT) with or without autologous bone-marrow
transplantation. The most frequent adverse event (AE) reported was
mild/moderate musculoskeletal (bone) pain in 14% at doses of 0.35 to
11.5 ug/kg/day and in 24% at doses of 23 to 115 ug/kg/day. There were
reversible elevations in serum uric acid, lactate dehydrogenase, and
alkaline phosphatase, but no clinical sequelae, unexpected tumor
progression, or negative effect on the benefits of CT. Patients did not
develop flu-like symptoms, fluid retention, pericarditis, or hypoxia as
reported with other cytokines. Now we have reviewed post-marketing
safety reports to assess the safety profile in a larger population. From
February 1991 to October 1993, greater than 339,000 patients have been
treated with Filgrastim. In this period, there have been only 733 AEs
reported spontaneously to the manufacturer under a worldwide
post-marketing safety surveillance program. Seventy-five percent of
these reports are in the oncology setting; other indications included
HIV infection, severe chronic neutropenia, and drug induced
agranulocytosis. Reports were originated by health professionals (88%),
consumers (9%), and literature reports (3%). The two most frequently
reported clinical events were bone pain (reporting frequency, 1/4100)
and rash (reporting frequency, 1/5250). There have also been rare
reports of systemic allergic-type reactions (reporting frequency less
than 1/7000). Two years after marketing approval, the safety profile of
Filgrastim remains comparable with that seen in clinical trials and
Filgrastim appears to be well tolerated.
DE Antineoplastic Agents/ADVERSE EFFECTS Bone Marrow Transplantation
Granulocyte Colony-Stimulating Factor/*ADVERSE EFFECTS/ THERAPEUTIC USE
Human Neutropenia/THERAPY Transplantation, Autologous MEETING
ABSTRACT CLINICAL TRIAL
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).